Drug intelligence / Profile preview

PLD-102

Development stage: Preclinical
Lead developer: Pelemed
Modality: Small Molecules
Administration: Oral

Overview

PLD-102 (also known as PLM-102) is a third-generation small molecule inhibitor of Fms-like tyrosine kinase 3 (FLT3) being developed by Pelemed for the treatment of Acute Myeloid Leukemia (AML). It is specifically designed to overcome resistance mechanisms associated with earlier-generation FLT3 inhibitors by targeting drug-resistant mutations, including the FLT3-ITD/F691L gatekeeper mutation and the FLT3-ITD/D835Y activation loop mutation. As of early 2024, the program is in the discovery phase of development.

Targets

RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)

Beyond the preview

Go deeper on PLD-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLD-102.

Explore the full profile